Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1, Open-Label, Multicenter, Dose Escalation Study of PRT1419 Injection as Monotherapy or in Combination With Azacitidine or Venetoclax in Patients With Relapsed/Refractory Myeloid or B-cell Malignancies

Next Previous
X
Search
Trial Profile

A Phase 1, Open-Label, Multicenter, Dose Escalation Study of PRT1419 Injection as Monotherapy or in Combination With Azacitidine or Venetoclax in Patients With Relapsed/Refractory Myeloid or B-cell Malignancies

Status: Discontinued
Phase of Trial: Phase I

Latest Information Update: 05 Feb 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Azacitidine (Primary) ; Azacitidine (Primary) ; PRT 1419 (Primary) ; Venetoclax (Primary)
  • Indications Acute myeloid leukaemia; Chronic lymphocytic leukaemia; Chronic myelomonocytic leukaemia; Haematological malignancies; Myelodysplastic syndromes; Myeloproliferative disorders; Non-Hodgkin's lymphoma
  • Focus Adverse reactions
  • Sponsors Prelude Therapeutics

    • Most Recent Events

    • 29 Jan 2024 Status changed from active, no longer recruiting to discontinued.
    • 16 Nov 2023 Status changed from recruiting to active, no longer recruiting.
    • 03 Aug 2023 According to a Prelude Therapeutics media release, the Company will provide a clinical update on PRT1419 by year end.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top